

Regulation by Interleukin-10 and Interleukin-4 of Cyclooxygenase-2 Expression in Human Neutrophils

By Hiroaki Niiro, Takeshi Otsuka, Kenji Izuhara, Kunihiro Yamaoka, Koichi Ohshima, Tadashi Tanabe, Shuntaro Hara, Yoshiaki Nemoto, Yosuke Tanaka, Hitoshi Nakashima, and Yoshiyuki Niho

Neutrophils are important effector cells of acute inflammation because of their potential capacity to synthesize various proinflammatory mediators, and inhibition of their production is expected to result in anti-inflammatory effects. In this study, we investigate the effects of the anti-inflammatory cytokines, interleukin-10 (IL-10) and IL-4, on prostanoind synthesis in human neutrophils. Neutrophils isolated from healthy donors constitutively produced a small amount of prostaglandin E₂ (PGE₂) without any stimulations, whereas they produced a large amount of PGE₂ after lipopolysaccharide (LPS) stimulation. IL-10 and IL-4 selectively inhibited their LPS-induced PGE₂ production. Inhibition by both cytokines occurred at an early stage of LPS stimulation. Anti-IL-10 treatment of LPS-stimulated neutrophils resulted in

enhanced PGE₂ production. LPS-induced PGE₂ and thromboxane B₂ (TXB₂) production in aspirin-treated neutrophils was significantly inhibited by IL-10, IL-4, and NS-398. Moreover, IL-10 and IL-4 inhibited LPS-induced cyclooxygenase (COX) activity in neutrophils. Western blot and immunocytochemical analysis showed that COX-2 protein was clearly induced in LPS-stimulated neutrophils and that its induction was inhibited by both IL-10 and IL-4. Moreover, both of these cytokines inhibited COX-2 mRNA expression in LPS-stimulated neutrophils. These results raise the possibility that these two cytokines may both offer potent clinical utility as anti-inflammatory agents in the future.

© 1997 by The American Society of Hematology.

IT HAS RECENTLY been understood that interleukin-10 (IL-10) and IL-4 are anti-inflammatory cytokines. This is due, at least in part, to their potent biologic effects on monocytes/macrophages. Both cytokines efficiently inhibit the production of proinflammatory cytokines such as tumor necrosis factor- α (TNF- α), IL-1 α , IL-1 β , IL-6, and IL-8 by monocytes/macrophages.¹⁻⁵ Additionally, they significantly inhibit the production of other proinflammatory mediators, such as reactive oxygen intermediates, reactive nitrogen intermediates, and prostaglandins (PGs) in monocytes/macrophages.^{4,6-12} On the other hand, IL-10 and IL-4 enhance the production of IL-1 receptor antagonist (IL-1ra) possessing an effective anti-inflammatory property.^{1,13,14}

Neutrophils are the first effector cells that migrate into tissue sites during various inflammatory reactions. The cells have long been considered to be terminally differentiated cells and are capable of performing little, if any, de novo protein synthesis. However, as recently reported,¹⁵ it is becoming evident that following appropriate stimuli, these cells can express substantial amounts of mRNA for cytokines, including TNF- α , IL-1 β , IL-8, IL-12, IL-1ra, macrophage inflammatory protein-1 α (MIP-1 α), MIP-1 β , IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Even though production of such cytokines in neutrophils is considerably less than that in monocytes on a single-cell basis, it must be noted that neutrophils quantitatively dominate over monocytes within inflamed tissues. In rheumatoid arthritis (RA) patients, an increase in the absolute number of neutrophils, together with their induced function, have both been shown to be closely related to the disease activity of arthritis.^{16,17} Thus, inhibition of the function of these neutrophils is expected to control such inflammatory diseases.

Cyclooxygenase (COX) is a key rate-limiting enzyme in the biosynthesis of PGs and thromboxane from arachidonic acid (AA). Recent evidence has shown that COX exists in at least two distinct isoforms, a constitutive form (COX-1) and an inducible form (COX-2). COX-1 is constitutively expressed in various cell types and is believed to maintain physiologic homeostatic conditions, whereas COX-2 can be inducibly expressed in several cell populations following

extracellular stimuli such as cytokines, mitogens, and lipopolysaccharide (LPS)¹⁸⁻²²; thus, this isoform appears to play more pivotal roles in inflammatory situations. We have previously shown that LPS-stimulated monocytes inducibly expressed COX-2 at both the mRNA and the protein levels, and that such expression was significantly inhibited by IL-10 and IL-4.²³ It was recently shown that in the rat pleurisy model of acute inflammation, COX-2 protein existed mainly within the infiltrating neutrophils at inflamed lesions.²⁴ Recent reports have shown that IL-10 and IL-4 not only inhibit the production of cytokines including TNF- α , IL-1 α , IL-1 β , IL-8, and IL-12, but also enhance IL-1ra production in neutrophils.²⁵⁻³¹ However, there have been no reports that clearly demonstrate the neutrophil-derived COX-2 expression in the human system, or the regulation by IL-10 and IL-4 of neutrophil-derived prostanoid synthesis. In this study, we have investigated these aspects and offer further discussion on the mechanism of the anti-inflammatory functions of IL-10 and IL-4.

From the First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka; the Department of Human Genetics, National Genetic Institute, Shizuoka; the Department of Pathology, School of Medicine, Fukuoka University, Fukuoka; and the Department of Pharmacology, National Cardiovascular Center Research Institute, Osaka, Japan.

Submitted May 9, 1996; accepted October 9, 1996.

Supported in part by grants-in-aid for Scientific Research on Priority Areas from the Ministry of Education, Science and Culture of Japan and by the Special Coordination Funds for Science and Technology.

Address reprint requests to Takeshi Otsuka, MD, First Department of Internal Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-82, Japan.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.

0006-4971/97/8905-0006\$3.00/0

MATERIALS AND METHODS

Reagents. Fetal bovine serum (FBS) and RPMI 1640 were purchased from GIBCO (Grand Island, NY) and Nissui Chemical Co (Tokyo, Japan), respectively. RPMI 1640 supplemented with FBS (10%), glutamine (1 mmol/L), penicillin (100 U/mL), and kanamycin (80 µg/mL) was used for all experiments except for the instances noted. LPS from *Escherichia coli* 0111:B4, purified by the Westphal method, was obtained from Difco (Detroit, MI). AA and aspirin were obtained from Sigma (St Louis, MO). NS-398 was obtained from Biomol Research Laboratories, Inc (Plymouth Meeting, PA). Human recombinant (r) IL-4 was generously provided by Schering-Plough Research (Bloomfield, NJ). Human rIL-10 was kindly provided by Dr K.W. Moore (DNAX, Palo Alto, CA). The anti-IL-10 monoclonal antibody (MoAb) 19F1 and isotype-matched control antibody were kindly provided by Dr J. S. Abrams (DNAX). The anti-COX-2 was a mouse MoAb (Transduction Laboratories, Lexington, KY) that was found to be highly specific. The antibody did not cross-react with human COX-1 and it had no apparent cross-reactivity against other human cell proteins.

Isolation and culture of human neutrophils. To minimize monocyte and platelet contamination, highly purified neutrophils were prepared as recently described,²⁷ with some modifications. Briefly, 30 mL of heparinized venous blood of healthy donors was mixed with 20 mL of 6% dextran/0.9% sodium chloride. After dextran sedimentation of erythrocytes, the plasma was layered onto Ficoll-Hypaque (Pharmacia LKB Biotechnology Inc, Piscataway, NJ), centrifuged, and the mononuclear cells at the interface were carefully removed with a Pasteur pipette. To further purify neutrophils, the remainder of the Ficoll-Hypaque phase (containing monocytes) was completely removed with a fresh Pasteur pipette. The tube wall was carefully washed with phosphate-buffered saline (PBS), and the cell pellet on the bottom of the tube was suspended in 5 mL of PBS. The suspension was transferred to a new tube and the residual contaminating erythrocytes were eliminated by hypotonic lysis. Subsequently, the cells were layered onto NycoPrep 1.063 (Nycomed Pharma, Oslo, Norway), centrifuged, and the NycoPrep phase (containing platelets) was completely removed with a fresh Pasteur pipette. The recovered neutrophils were washed three times and resuspended at a density of 1×10^7 cells/mL in RPMI 1640 media. The remaining cells contained more than 99.5% neutrophils according to morphology and were more than 98% viable as determined by trypan blue exclusion. In this neutrophil preparation, IL-6, a good marker for monocyte contamination,^{15,27} was undetectable even in the presence of LPS (data not shown). These cells were cultured in RPMI 1640 media with 10% FBS at 37°C in a humidified atmosphere with 5% CO₂ at a cell density of 1×10^6 cells/mL, in all of the experiments.

Radioimmunoassay (RIA) for PGE₂ and thromboxane B₂ (TXB₂). Analysis of PGE₂ and TXB₂ levels in the supernatants of neutrophils (1×10^6 cells) was performed with a commercially available RIA kit (New England Nuclear, Boston, MA), as described elsewhere.⁸

Analysis of COX activity. Neutrophils (1×10^6 cells) were incubated in RPMI 1640 containing 10% FBS with either IL-10 or IL-4 in the presence or absence of LPS for 18 hours. The medium was removed after the incubation, and cells were incubated in fresh medium containing AA (30 µmol/L) for 10 minutes to determine COX activity, as described by Fu et al.³² Levels of PGE₂ were determined using RIA.

Western blot analysis. Neutrophils (1×10^7 cells) were incubated for 18 hours with either IL-10 or IL-4 in the presence or absence of LPS. After incubation, cells were obtained and lysed in 150 µL of solubilization buffer at 25°C (1% Tween 20, 10 mmol/L phenylmethylsulfonyl fluoride, and 50 mmol/L Tris-HCl, pH 8.0).

Cell lysates were then sonicated for 15 seconds and centrifuged at 15,000g for 15 minutes. Supernatants were subsequently mixed 1:1 with sodium dodecyl sulfate (SDS) sample buffer. Equal amounts of protein (25 µg) were then separated on a 9% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was then blocked with PBS containing 5% skim milk and 0.1% Tween 20, and then incubated with 0.25 µg/mL of mouse anti-COX-2 MoAb in the blocking buffer at 25°C for 2 hours. The membrane was subsequently incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:1,000 dilution) and analyzed using an Amersham enhanced chemiluminescence (ECL) system (Amersham, Arlington Heights, IL). Fuji X-omat AR film (Fuji Photo Film Co, Tokyo, Japan) with cassette closure times of 5 to 10 minutes resulted in adequate exposure to visualize the bands.

Immunocytochemistry. Neutrophils (1×10^7 cells) were incubated for 18 hours with either IL-10 or IL-4 in the presence or absence of LPS, and deposited on a glass slide by using a Cytospin II (Shandon Southern Instruments, Inc, Sewickley, PA). After air-drying, the slides were fixed for 30 minutes in ice-cold acetone. After rinsing in Tris-buffered saline (TBS), the slides were blocked with a 1:50 dilution of normal horse serum for 30 minutes at 37°C, then treated for 1 hour at 37°C with mouse anti-COX-2 MoAb or isotype-matched control antibody. After incubation, preparations were rinsed three times with TBS, overlaid with biotinylated horse anti-mouse IgG (1:200; Vector Laboratories Inc, Burlingame, CA), incubated for 30 minutes, and rinsed three times with TBS. The slides were then treated by streptavidin conjugated to alkaline phosphatase for 30 minutes at 37°C, rinsed three times with TBS, and overlaid with naphthol-AS-BI-phosphoric acid 100 mg/mL in N,N-dimethyl formamide (Sigma, St Louis, MO) for 15 minutes at 37°C to allow for color development. The slides were then fixed by 20% paraformaldehyde in TBS for 20 minutes, rinsed three times with TBS, and stained with Mayer's hematoxylin.


Northern blot analysis. Neutrophils (5×10^7 cells) were incubated for 5 hours with either IL-10 or IL-4 in the presence or absence of LPS, and total cellular RNA was isolated by the acid guanidium thiocyanate/phenol/chloroform extraction method as described by Chomczynski and Sacchi.³³ Ten micrograms of total RNA was fractionated on 1.5% agarose gel containing 2.2 mol/L formaldehyde and was subsequently transferred to a zeta-Probe blotting membrane (BioRad, Richmond, CA). Hybridization was done (overnight at 42°C) in 5× SSPE containing 50% formamide, 5× Denhardt's solution, 1% SDS, and 0.2 mg/mL of denatured salmon sperm DNA. The filter was washed in 2× SSC, 0.1% SDS at 50°C (twice, 25 minutes each time) followed by 0.5× SSC, 0.1% SDS at 50°C (twice, 15 minutes each time). The cDNA probe used was the 1.5-kb fragment of human COX-2.³⁴ The probe was labeled using a random primer labeling kit (Takara Shuzo, Kyoto, Japan) with [³²P]dCTP. To estimate the levels of each mRNA, the filters were exposed to a Fuji imaging plate (BAS-III; Fuji Photo Film Co) for 12 hours. The hybridized bands were visualized with the BAS-2000 Bio-image analyzer (Fuji Photo Film Co).

Statistical analysis. Student's *t*-test was used to compare control and experimental groups. Values of *P* > .05 were considered not significant.

RESULTS

Effects of IL-10 and IL-4 on neutrophil-derived PGE₂ production. To this end, we first determined the effects of IL-10 and IL-4 on PGE₂ production in human neutrophils. As shown in Fig 1, in the absence of any stimuli, neutrophils constitutively produced small but detectable amounts of

Fig 1. Effects of IL-10 and IL-4 on neutrophil-derived PGE₂ production. Human neutrophils (1×10^6 cells) were cultured for 24 hours with the indicated concentrations of IL-10 and IL-4 in the presence or absence of LPS (100 ng/mL). RIA for PGE₂ was performed as described in Materials and Methods. Results are expressed as the mean \pm SEM of triplicate cultures. Similar results were obtained in three separate experiments. * $P < .05$, ** $P < .01$ (compared with LPS only).



PGE₂ in the culture supernatants. IL-10 and IL-4 at optimal concentrations did not affect the constitutive PGE₂ production in neutrophils. Then, after activation by LPS, the cells inducibly produced high levels of PGE₂. Interestingly, both cytokines significantly inhibited LPS-induced PGE₂ production in neutrophils. The inhibitory effects of both cytokines followed a dose-dependent fashion. We next determined the kinetics for the regulation by IL-10 and IL-4 of neutrophil-derived PGE₂ production. As shown in Fig 2, PGE₂ secretion could be detected 6 hours after LPS stimulation and this continued to increase up until 24 hours. Significant inhibition by both cytokines could already be observed 6 hours after LPS stimulation. Moreover, we determined the effect of neutralizing anti-IL-10 MoAb on neutrophil-derived PGE₂ production. As shown in Fig 3, constitutive PGE₂ production

in neutrophils was not significantly affected by anti-IL-10 treatment. By contrast, LPS-induced PGE₂ production in neutrophils was clearly enhanced by this treatment. In addition, the inhibition by IL-10 of LPS-induced PGE₂ production in neutrophils was almost abrogated by anti-IL-10 treatment, whereas the inhibition by IL-4 was not affected by this treatment.

Effects of IL-10 and IL-4 on COX-2-derived PGE₂ and TXB₂ production in neutrophils. Recent studies have shown that in several cell types, LPS-induced prostanoid synthesis was mainly caused by the COX-2 expression. To inactivate endogenous COX-1, we treated neutrophils with aspirin for 2 hours,³⁵ and determined their PGE₂ and TXB₂ production. As shown in Fig 4, after activation by LPS, the cells exhibited a remarkable PGE₂ and TXB₂ production,




Fig 2. Kinetic studies for the inhibition by IL-10 and IL-4 of PGE₂ production in LPS-stimulated neutrophils. Human neutrophils (1×10^6 cells) were cultured for 24 hours with or without 10 ng/mL of IL-10 or IL-4 in the presence of LPS (100 ng/mL). RIA for PGE₂ was performed as described in Materials and Methods. Results are expressed as the mean \pm SEM of triplicate cultures. Similar results were obtained in two separate experiments.




Fig 3. Effects of neutralizing anti-IL-10 MoAb on neutrophil-derived PGE₂ production. Unstimulated or LPS-stimulated (100 ng/mL) neutrophils (1×10^6 cells) were cultured for 24 hours with neutralizing anti-IL-10 MoAb 19F1 or isotype-matched control antibody (10 μ g/mL) in the presence or absence of 10 ng/mL of IL-10 or IL-4. RIA for PGE₂ was performed as described in Materials and Methods. Results are expressed as the mean \pm SEM of triplicate cultures. Similar results were obtained in two separate experiments. * $P < .05$, ** $P < .01$ (compared with LPS only).




Fig 4. Effects of IL-10 and IL-4 on COX-2-derived PGE₂ (A) and TXB₂ (B) production in neutrophils. Human neutrophils (1×10^6 cells) were treated for 2 hours in the presence of aspirin (500 μ mol/L) to inactivate endogenous COX-1, washed three times with PBS, and then cultured for 24 hours with medium, LPS (100 ng/mL), LPS plus IL-4 (10 ng/mL), LPS plus IL-10 (10 ng/mL), or LPS plus NS-398 (1 μ mol/L). RIA for PGE₂ (A) and TXB₂ (B) was performed as described in Materials and Methods. Similar results were obtained in two separate experiments.

which was then significantly inhibited by IL-10 and IL-4. In addition, this LPS-induced prostanoid production was almost completely inhibited by a selective COX-2 inhibitor, NS-398.^{36,37} Taken together, these results indicate that prostanoid synthesis in LPS-stimulated neutrophils was regulated at the COX-2 level, and both IL-10 and IL-4 were able to act at this level.

Effects of IL-10 and IL-4 on COX activity in neutrophils.

We next determined the effects of both cytokines on neutrophil-derived COX activity. As shown in Fig 5, even in the absence of LPS, neutrophils constitutively showed a weak yet significant COX activity. Neither IL-10 nor IL-4 affected this activity. After activation by LPS, the cells exhibited a significant increase in COX activity. Then, both cytokines significantly inhibited this LPS-induced COX activity in neutrophils.

Effects of IL-10 and IL-4 on COX-2 protein expression in




Fig 5. Effects of IL-10 and IL-4 on neutrophil-derived COX activity. Human neutrophils (1×10^6 cells) were cultured with or without 10 ng/mL of IL-10 or IL-4 in the presence or absence of LPS (100 ng/mL). After 18 hours, the culture medium was removed, and then fresh medium containing 30 μ mol/L AA was added on top of the cell layer. After incubation for 10 minutes, the culture medium was assayed for PGE₂ by RIA. Results are expressed as a percentage of COX activity of unstimulated neutrophils. Similar results were obtained in two separate experiments.

neutrophils. We next determined the effects of IL-10 and IL-4 on COX-2 protein expression in neutrophils by using Western blot analysis. As shown in Fig 6, unstimulated neutrophils exhibited no distinct COX-2 protein and neither of the cytokines affected this expression. By contrast, after stimulation by LPS, the expression of this protein was drastically induced and both cytokines significantly inhibited this expression.

Immunocytochemical analysis of neutrophil-derived COX-2 protein. To further confirm the findings of Western blot studies, we next performed immunocytochemical analysis of neutrophil-derived COX-2 protein. Unstimulated neutrophils exhibited no specific staining of COX-2 protein (Fig 7A). After activation by LPS, neutrophils clearly demonstrated a significant staining for immunoreactive COX-2 protein (Fig 7B). However, as recently reported,²⁴ it was noted that the intensity of staining in each cell varied to some extent. By contrast, LPS-stimulated neutrophils treated with IL-10 or IL-4 exhibited less immunoreactive COX-2 protein (Fig 7C and D). The level of isotype-matched control antibody binding was low, showing the specificity of the immunoreactive COX-2 localization (Fig 7E).




Fig 6. Western blot of neutrophil-derived COX-2 protein expression. Human neutrophils (1×10^7 cells) were cultured with or without 10 ng/mL of IL-10 or IL-4 in the presence or absence of LPS (100 ng/mL). After 18 hours, cells were procured, cell lysates were centrifuged, and equal amounts of protein (25 μ g) were then separated on a 9% SDS-PAGE and subjected to Western blot analysis with 0.25 μ g/mL anti-COX-2 MoAb. Similar results were obtained in three separate experiments.




Fig 7. High-power (original magnification $\times 400$) photomicrographs of immunolocalization of neutrophil-derived COX-2 protein. Human neutrophils (1×10^7 cells) were cultured for 18 hours with 10 ng/mL of IL-10 or IL-4 in the presence or absence of LPS (100 ng/mL). The cells were deposited on a glass slide and stained with anti-COX-2 MoAb (A, medium; B, LPS; C, LPS + IL-4; D, LPS + IL-10) or control antibody (E).

Effects of IL-10 and IL-4 on COX-2 mRNA expression in neutrophils. Because COX-2 protein has been shown to be also regulated at the RNA level in various cell types,¹⁹⁻²³ we thus determined COX-2 mRNA expression in neutrophils. As shown in Fig 8, unstimulated neutrophils did not express COX-2 mRNA, and neither IL-10 nor IL-4 affected this expression. By contrast, after activation by LPS, COX-2 mRNA was drastically induced, and both cytokines significantly inhibited this expression.

DISCUSSION

In the present study, we investigated the mechanism of neutrophil-derived prostanoid synthesis and its regulation by IL-10 and IL-4. Consistent with previous reports,^{38,39} human neutrophils inducibly produced large amounts of PGE₂ and TXB₂ after activation by LPS, although the level of production on a cell basis in neutrophils was approximately 10-fold less than that in monocytes.⁸ IL-10 and IL-4 inhibited LPS-induced prostanoid production to the same degree. In addition to LPS, both TNF α and IL-1 β were previously shown to activate neutrophil functions.^{25,40} Both cytokines, like LPS, stimulated neutrophils to produce a significant amount of PGE₂, which was again inhibited by IL-10 and IL-4 (data not shown). The inhibitory effects of IL-10 and IL-4 have also been reported regarding the production of

cytokines such as TNF- α , IL-1 α , IL-1 β , IL-8, IL-12, MIP-1 α , and MIP-1 β in LPS-stimulated neutrophils.²⁵⁻³⁰ Compared with the inhibition of cytokine production, IL-10 and IL-4 seemed to be rather effective at inhibiting neutrophil-derived prostanoid production. On the other hand, the effects of both these cytokines on neutrophil function are not always inhibitory. IL-10 and IL-4 have been found to rather enhance IL-1ra production in LPS-stimulated neutrophils.^{29,31} Based on these findings, the effects of the two cytokines on neutrophil functions appear to be virtually identical to those on monocyte functions. However, that is not the case for superoxide anion production. In monocytes, IL-10 significantly inhibited the expression of NADPH oxidase subunit gp91-phox,⁴¹ whereas in neutrophils, IL-10 had no effect on gp91-phox expression.²⁹

After activation by LPS, monocytes are able to produce endogenous IL-10, which in turn regulates their own production of various effector molecules.^{1,3,8} In the present study, the same is true for neutrophils. Anti-IL-10 treatment of LPS-stimulated neutrophils resulted in enhanced PGE₂ production. After activation by LPS, our neutrophil preparation contained detectable amounts of IL-10, but not IL-6 (data not shown), suggesting that endogenous IL-10 was released from neutrophils, but not contaminating monocytes. Recently, in the mouse system, LPS-induced IL-10 production




Fig 8. Effects of IL-10 and IL-4 on neutrophil-derived COX-2 mRNA expression. Human neutrophils (5×10^7 cells) were cultured with or without 10 ng/mL of IL-10 or IL-4 in the presence or absence of LPS (100 ng/mL). After 5 hours, total RNA was isolated and analyzed by Northern blot using a COX-2 probe. Similar results were obtained in two separate experiments.

in neutrophils was clearly demonstrated.⁴² In our study, the inhibitory effect of IL-4 on LPS-induced PGE₂ production in neutrophils was not explained by the secondary induction of endogenous IL-10. Thus, IL-10 and IL-4 independently regulate neutrophil-derived prostanoid production.

COX is a key rate-limiting enzyme in the synthesis of PGE₂ and TXB₂ from AA. Recent studies have shown that COX exists in at least two different isoforms, COX-1 and COX-2. Using recent sensitive approaches such as immunocytochemistry, it has been shown that in the rat pleurisy model of acute inflammation, the COX-2 protein clearly existed, mainly within infiltrating neutrophils at inflamed lesions.²⁴ With regard to human systems, there have been few reports concerning neutrophil-derived COX-2 expression. COX-2 was shown to be significantly expressed in the synovial tissues of RA patients, especially within infiltrating mononuclear cells, endothelial cells of blood vessels, and subsynovial fibroblast-like cells.⁴³ Considering the significance of neutrophil functions in RA disease activity,^{16,17} further investigations are essential for clarifying the pathogenesis of RA. In human neutrophils, immunoreactive COX-2 protein was clearly expressed within LPS-stimulated neutrophils, and treatment with IL-10 or IL-4 almost completely inhibited this expression. Similar findings were also obtained by Western blot analysis. On the other hand, in our system, COX-1 protein expression in neutrophils was hardly detected (data not shown). Considering that unstimulated neutrophils produced a small but detectable amount of PGE₂, it is probable that the cells express COX-1 protein very weakly. Thus, our findings that IL-10 and IL-4 bore no effect on constitutive PGE₂ production in neutrophils suggested that perhaps neither of these cytokines has any effect on COX-1 protein expression. Together with the data of Fig 4, these findings

indicate that IL-10 and IL-4 selectively inhibit COX-2 protein expression in neutrophils.

In our study, COX-2 mRNA was inducibly expressed in LPS-stimulated neutrophils, and this expression was almost completely inhibited by IL-10 and IL-4. The gene expression is thought to be regulated at the transcriptional and/or post-transcriptional level. We previously showed that in monocytes, the regulation by IL-10 and IL-4 of COX-2 mRNA expression occurred at both levels.²³ However, in the present study we failed to determine whether a similar mechanism was involved in neutrophils for the following reasons. First, experiments with actinomycin D showed that significant inhibition by both cytokines of COX-2 mRNA expression occurred at early time points after LPS stimulation, and the rate of mRNA degradation could not be correctly calculated (data not shown). A similar situation was previously reported regarding the inhibition by IL-10 of TNF- α production in mouse macrophages.⁴⁴ Second, as recently shown in neutrophil-derived cytokines,²⁷ transcription of the COX-2 gene was hardly detected (data not shown). This is possibly because of low transcriptional rates in neutrophils, compared with those in monocytes. Recent reports have shown that IL-10 inhibited the production of MIP-1 α , MIP-1 β , and IL-8 in LPS-stimulated neutrophils by accelerating the degradation of mRNA.^{26,27} However, in those reports, data on the transcription were not provided. To our knowledge there have been no reports on the effect of IL-4 on gene transcription and mRNA stability in neutrophils. Based on these findings, we, at present, cannot rule out the possibility that IL-10 and IL-4 may regulate the LPS-induced COX-2 mRNA expression in neutrophils as well as in monocytes at both the transcriptional and posttranscriptional levels.

PGs are potent proinflammatory mediators that cause vasodilatation and hyperalgesia *in vivo*, these being the characteristic features of acute inflammation. It is now evident that neutrophils represent an important source of PGs in acute inflamed tissues. Recent studies have noted that those drugs showing selective inhibition of COX-2 expression exhibited potent anti-inflammatory effects *in vivo*, with fewer side effects.⁴⁵ Therefore, our present findings that IL-10 and IL-4 significantly inhibited prostanoid production in LPS-stimulated neutrophils by selectively inhibiting COX-2 expression raise the possibility that both cytokines may offer clinical utility as anti-inflammatory agents in the future.

ACKNOWLEDGMENT

The authors thank Drs Toshihiro Miyamoto and Kei Ikeda (First Department of Internal Medicine, Kyushu University, Fukuoka, Japan) for helpful discussion, and K. Miller (Royal English Language Centre, Fukuoka, Japan) for proofreading the English used in this manuscript.

REFERENCES

- Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. *Annu Rev Immunol* 11:165, 1993
- Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. *J Immunol* 147:3815, 1991

3. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. *J Exp Med* 174:1209, 1991
4. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA: Potential antiinflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor α , interleukin 1 and prostaglandin E_2 . *Proc Natl Acad Sci USA* 86:3803, 1989
5. te Velde AA, Huijbens RJF, Heije K, de Vries JE, Figdor CG: Interleukin-4 (IL-4) inhibits secretion of IL-1 β , tumor necrosis factor- α and interleukin-6 by human monocytes. *Blood* 76:1392, 1990
6. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. *J Exp Med* 174:1549, 1991
7. Niho Y, Niiro H, Kuga S, Nemoto Y, Otsuka T: Interleukin-10 inhibits functions of activated human monocytes, in Abraham NG, Shadduck RK, Levine AS, Takaku F (eds): *Molecular Biology of Haematopoiesis*, vol 3. Andover, UK, Intercept, 1994, p 621
8. Niiro H, Otsuka T, Kuga S, Nemoto Y, Abe M, Hara N, Nakano T, Ogo T, Niho Y: IL-10 inhibits prostaglandin E_2 production by lipopolysaccharide-stimulated monocytes. *Int Immunol* 6:661, 1994
9. Gazzinelli RT, Oswald IP, James SL, Sher A: IL-10 inhibits parasite killing and nitrogen oxide production by IFN- γ -activated macrophages. *J Immunol* 148:1792, 1992
10. Lehn M, Weiser WY, Engelhorn S, Gillis S, Remold HG: IL-4 inhibits H_2O_2 production and antileishmanial capacity of human cultured monocytes mediated by IFN- γ . *J Immunol* 143:3020, 1989
11. Abramson SL, Gallin JI: IL-4 inhibits superoxide production by human mononuclear phagocytes. *J Immunol* 144:625, 1990
12. Bogdan C, Vodovotz Y, Paik J, Xie Q-w, Nathan C: Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. *J Leukoc Biol* 55:227, 1994
13. Orino E, Sone S, Nii A, Ogura T: IL-4 up-regulates IL-1 receptor antagonist gene expression and its production in human blood monocytes. *J Immunol* 149:925, 1992
14. Fenton MJ, Buras JA, Donnelly RP: IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. *J Immunol* 149:1283, 1992
15. Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. *Immunol Today* 16:21, 1995
16. Yasuda M, Kihara T, Wada T, Shiokawa S, Furuta E, Suenaga Y, Nonaka S, Nobunaga M, Yoshioka K, Isayama T: Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient. *Arthritis Rheum* 37:145, 1994
17. Vidarsson B, Geirsson AJ, Öundurson PT: Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. *Am J Med* 98:589, 1995
18. DeWitt DL: Prostaglandin endoperoxidase synthase: Regulation of enzyme expression. *Biochim Biophys Acta* 1083:121, 1991
19. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc Natl Acad Sci USA* 88:2692, 1991
20. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J Biol Chem* 266:12866, 1991
21. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. *Proc Natl Acad Sci USA* 89:7384, 1992
22. Hempel SL, Morick MM, Hunninghake GW: Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. *J Clin Invest* 93:391, 1994
23. Niiro H, Otsuka T, Tanabe T, Hara S, Kuga S, Nemoto Y, Tanaka Y, Nakashima H, Kitajima S, Abe M, Niho Y: Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: Its underlying mechanism in comparison with interleukin-4. *Blood* 85:3736, 1995
24. Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, Willoughby DA: Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. *Br J Pharmacol* 113:693, 1994
25. Cassatella MA, Meda L, Bonora S, Ceska M, Constatin G: Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. *J Exp Med* 178:2207, 1993
26. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL: Regulation of neutrophil-derived chemokine expression by IL-10. *J Immunol* 152:3559, 1994
27. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM: Interleukin-10 inhibits interleukin-8 production in human neutrophils. *Blood* 83:2678, 1994
28. Cassatella MA, Meda L, Gasperini S, D'Andrea A, Ma X, Trinchieri G: Interleukin-12 production by human polymorphonuclear leukocytes. *Eur J Immunol* 25:1, 1995
29. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S: Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. *J Exp Med* 179:1695, 1994
30. Wertheim WA, Kunkel SL, Standiford TJ, Burdick MD, Becker FS, Wilke CA, Gilbert AR, Strieter RM: Regulation of neutrophil-derived IL-8: The role of prostaglandin E_2 , dexamethasone, and IL-4. *J Immunol* 151:2166, 1993
31. Re F, Mengozzi M, Muzio M, Dinarello CA, Mantovani A, Colotta F: Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphonuclear cells. *Eur J Immunol* 23:570, 1993
32. Fu J-Y, Masferrer JL, Seibert K, Raz A, Needleman P: The induction and suppression of prostaglandin H_2 synthase (cyclooxygenase) in human monocytes. *J Biol Chem* 265:16737, 1990
33. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156, 1987
34. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. *Eur J Biochem* 221:889, 1994
35. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D: Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. *J Biol Chem* 267:25934, 1992
36. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. *Prostaglandin* 47:55, 1994
37. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, di Giamberardino M, Cipollone F, Cuccurullo F, Patrino C, Patrignani P: Effects of the novel anti-inflammatory compounds, *N*-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human

- blood prostaglandin endoperoxide synthases. *Br J Pharmacol* 116:2429, 1995
38. Herrmann F, Lindemann A, Gauss J, Mertelsmann R: Cytokine-stimulation of prostaglandin synthesis from endogenous and exogenous arachidonic acids in polymorphonuclear leukocytes involving activation and new synthesis of cyclooxygenase. *Eur J Immunol* 20:2513, 1990
39. Weithmann KU, Jeske S, Schlotte Y: Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation. *Agents Actions* 41:164, 1994
40. Yagisawa M, Yuo A, Kitagawa S, Yazaki Y, Togawa A, Takaku F: Stimulation and priming of human neutrophils by IL-1 α and IL-1 β : Complete inhibition by IL-1 receptor antagonist and no interaction with other cytokines. *Exp Hematol* 23:603, 1995
41. Kuga S, Otsuka T, Niuro H, Nunoi H, Nemoto Y, Nakano T, Ogo T, Umei T, Niho Y: Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. *Exp Hematol* 24:151, 1996
42. Nill MR, Oberyszyn TM, Ross MS, Oberyszyn AS, Robertson FM: Temporal sequence of pulmonary cytokine gene expression in response to endotoxin in C3H/HeN endotoxin-sensitive and C3H/HeJ endotoxin-resistant mice. *J Leukoc Biol* 58:563, 1995
43. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 β , phorbol ester, and corticosteroids. *J Clin Invest* 93:1095, 1994
44. Bogdan C, Paik J, Vodovotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor- β and interleukin-10. *J Biol Chem* 267:23301, 1992
45. Arai I, Hamasaka Y, Futaki N, Takahashi S, Yosikawa K, Higuchi S, Otomo S: Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. *Res Commun Chem Pathol Pharmacol* 81:259, 1993